Align Laboratories, LLC

Align Laboratories, LLC was paid $1.01M by Medicaid between Nov 2020 and Jul 2023, across 98 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 25% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Louisiana

Rank by total paid#27 of 66

Median peer was paid$253K

This provider vs. median4.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	753	$15K
2021	24,801	$300K
2022	65,023	$567K
2023	9,329	$131K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	25%	6,896	4,160	$253K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	17%	3,763	2,306	$171K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	9.3%	4,519	2,439	$94K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	7.3%	6,211	3,788	$74K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	6.4%	2,013	749	$65K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	4.5%	6,974	4,154	$45K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	3.7%	1,133	583	$37K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	2.5%	1,728	1,135	$25K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	2.2%	2,532	1,400	$22K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	2.1%	2,515	1,384	$22K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	2.0%	2,549	1,397	$21K
87481		1.5%	1,652	600	$15K

86 more codes

87500		1.2%	1,482	$13K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.1%	1,859	$11K
87150		<1%	1,479	$9K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	2,261	$9K
87640		<1%	1,539	$8K
87641		<1%	1,483	$7K
86696		<1%	1,522	$7K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,169	$6K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	2,361	$6K
80053	Comprehensive metabolic panel	<1%	1,163	$5K
82575		<1%	1,589	$5K
86695		<1%	1,529	$5K
83719		<1%	673	$4K
86038		<1%	1,550	$4K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	231	$4K
87186		<1%	1,499	$4K
80074		<1%	953	$4K
80061	Lipid panel	<1%	1,395	$4K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,875	$4K
84702		<1%	1,634	$3K
80048	Basic metabolic panel (calcium, ionized)	<1%	1,410	$3K
87625		<1%	359	$3K
80076		<1%	1,363	$3K
87529		<1%	362	$3K
87581		<1%	400	$2K
87486		<1%	400	$2K
87541		<1%	400	$2K
87563		<1%	375	$2K
87511		<1%	437	$2K
87086	Culture, bacterial; quantitative colony count, urine	<1%	1,053	$2K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	249	$2K
83550		<1%	1,405	$2K
86592		<1%	1,095	$1K
86593		<1%	888	$1K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	282	$1K
87653		<1%	313	$1K
86803		<1%	910	$1K
83540		<1%	1,405	$1K
85652		<1%	671	$1K
81317		<1%	19	$1K
87340		<1%	875	$958.79
84439		<1%	317	$805.82
82565		<1%	822	$443.62
82310		<1%	800	$434.00
84295		<1%	822	$422.34
82374		<1%	800	$410.99
84132		<1%	798	$393.41
82947		<1%	907	$391.94
82435		<1%	800	$386.66
81308		<1%	19	$343.54
84520		<1%	820	$340.72
36415	Collection of venous blood by venipuncture	<1%	494	$291.09
86709		<1%	465	$287.85
86705		<1%	447	$241.93
80165		<1%	47	$223.38
84703		<1%	44	$210.92
86612		<1%	32	$196.36
84443	Thyroid stimulating hormone (TSH)	<1%	58	$148.81
85027		<1%	72	$141.46
83986		<1%	341	$123.05
81003		<1%	455	$111.95
86708		<1%	33	$109.36
86644		<1%	25	$94.34
86794		<1%	29	$80.34
81001		<1%	66	$69.43
83721		<1%	1,310	$66.64
86706		<1%	19	$55.61
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	<1%	127	$23.79
84460		<1%	17	$14.52
84075		<1%	17	$14.16
84450		<1%	17	$14.16
82040		<1%	17	$13.59
82247		<1%	17	$10.48
84155		<1%	17	$10.01
85014		<1%	24	$5.03
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	384	$0.32
81162		0%	19	$0.00
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	133	$0.00
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	0%	331	$0.00
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	0%	410	$0.00
81404		0%	22	$0.00
81405		0%	22	$0.00
81406		0%	22	$0.00
81479	Unlisted molecular pathology procedure	0%	22	$0.00
81408		0%	22	$0.00
81403		0%	22	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLUGO, KEVIN (OWNER)